http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107303306-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-233
filingDate 2016-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2020-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107303306-B
titleOfInvention Application of bupleurum or polysaccharide of processed product thereof as P multidrug resistance reversal agent
abstract The invention discloses an application of bupleurum or polysaccharide of processed products thereof as a P glycoprotein multidrug resistance reversal agent, and in vitro experiments show that bupleurum polysaccharide can obviously increase the uptake of MRP2 substrate cisplatin in HEK293 cells with high expression of MRP2, and can also obviously increase the uptake of P glycoprotein substrate rhodamine B in HEK293 cells with high expression of P glycoprotein; safety research shows that the bupleurum polysaccharide is basically nontoxic and does not influence the proliferation of HEK293 cells, so that the bupleurum polysaccharide or polysaccharide of a processed product thereof can be used for preparing medicines for inhibiting the activity of multidrug resistance protein-related protein 2 and P glycoprotein. The invention has the beneficial effects that: the sensitivity of the chemotherapy drugs to cancer cells is enhanced, the curative effect of the drugs is enhanced, the bupleurum polysaccharide is safe and non-toxic, and is expected to be developed into a tumor MDR reversal agent.
priorityDate 2016-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6694
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456987945
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2520
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549332
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID533728
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID84798
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID46367
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP14319
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP21441
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441203
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID887274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491185
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID52451
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54675776
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451954015
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23925
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6212
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506849
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID46367
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID197
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423512670
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID197
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP13568
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID985272
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID263
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449728501
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID843095
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID52451

Total number of triples: 48.